With reference to EGFR+ advanced NSCLC patients, in the ongoing ORCHARD trial, ~ 150 patients experiencing progression of disease after upfront osimertinib (mutant-selective EGFR inhibitor) will undergo a post-progression biopsy in order to be assigned to one of three arms (A, B, or C). Here, EGFR is linked to non-small cell lung carcinoma.